Horizon Pharma has received a Notice of Allowance from the U.S. Patent and Trademark Office for its application covering Vimovo tablets, a fixed-dose combination of delayed-release enteric-coated naproxen (a non-steroidal anti-inflammatory drug, or NSAID), and immediate-release ... Read more